Company Overview and News

 
Bannerman Resources well positioned to leverage nuclear sector recovery

2018-09-21 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) managing director Brandon Munro updates Proactive Investors on the uranium development company’s position in a deepening deficit within the nuclear sector.
BNNLF BMN

2
Bannerman Resources has new substantial shareholder in Tribeca Investment Partners

2018-09-18 proactiveinvestors.com.au
Bannerman Resources Limited (ASX:BMN) (NSX:BMN) has a new substantial shareholder with Sydney-based Tribeca Investment Partners Pty Ltd now holding an 8.73% stake.
PDN PALAY PALAF RTPPF RIO RIO PDN BNNLF RIO RTNTF BMN

2
Sale of Substantial Shareholding

2018-09-17 globenewswire
PERTH, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX: BMN; NSX: BMN) (Bannerman or the Company) advises that it has been notified of the sale by Resource Capital Fund IV and Resource Capital Fund VI (collectively, RCF) of the entirety of RCF’s residual shareholding in the Company, being 191,429,739 shares.
RTPPF RIO RIO BNNLF RIO RTNTF BMN

2
Bannerman Resources buoyed as uranium investors snap up RCF’s substantial stake

2018-09-17 proactiveinvestors.com.au
Bannerman Resources Limited’s (ASX:BMN) (NSX:BMN) substantial shareholder Resource Capital Fund (RCF) has sold its entire stake of more than 191 million shares in the uranium explorer and developer.
PDN PALAY PALAF RTPPF RIO RIO PDN RIO BNNLF RTNTF CCJ BMN

4
Ur-Energy : Asymmetric Risk/Reward Opportunity In The United States' Uranium Mining Industry

2018-08-16 seekingalpha - 4
There is an enormous amount of unfulfilled future demand; current utility inventories are nowhere near what is needed to satisfy that unfulfilled demand. Miners are also refusing to sign contracts.
PDN PALAY PALAF DOC PDN UEC BNNLF URG BMN

 
Bannerman Resources well-funded to advance its project amid uranium price rise

2018-07-27 proactiveinvestors.com.au
Bannerman Resources Limited (ASX:BMN) has reported a strong June quarter during which the company completed an $8 million heavily oversubscribed capital raising.
BNNLF CCJ BMN

69
Uranium Mining: The Competitive Landscape

2018-06-25 seekingalpha - 1
The operators in the Athabasca Basin, Canada, enjoy the highest-grade uranium deposits and have a geological edge over other uranium districts.
PALAY PEN RIO LAM BLT AZZ TOEYF SYH PDN UEXCF PALAF NXE UEC EFR BMN LMRXF FSY DNN PWURF CVV RIO BBL GVXXF BHPLF FCU SYHBF DYLLF RIO NXGEF BKY ISENF CVVUF WSTRF RTPPF FOSYF TOE RTNTF CCJ UUUU DYL PENMF UWEFF KVLQF TGRUF MGAFF PDN BHPBF FCUUF EU URG DML BKY MGA PUMGF BHP BNNLF 9888 BHP LAM

 
Bannerman Resources' managing director shares expert insights on uranium market

2018-06-19 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) managing director Brandon Munro speaks to Proactive Investors about the company's Etango Uranium Project in Namibia, and also provides insights on the wider uranium market.
BNNLF BMN

 
A$8 Million Capital Raising Heavily Oversubscribed

2018-06-08 globenewswire
PERTH, Australia, June 08, 2018 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN) (NSX:BMN) (Bannerman or the Company) is pleased to announce that it has received commitments to raise A$8 million gross proceeds through the placement of 173,913,043 new Bannerman shares at an issue price of A$0.046 per share (Placement). The Placement was made to both institutional and sophisticated investors.
BNNLF BMN

 
Bannerman Resources in heavily oversubscribed raising as institutions build positions

2018-06-08 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) continues to be well supported by the investment community, and will now raise $8 million in a heavily oversubscribed placement at 4.6 cents.
BNNLF BMN

 
Bannerman Resources in heavily oversubscribed raising as intuitions build positions

2018-06-08 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN; NSX:BMN) continues to be well supported by the investment community, and will now raise $8 million in a heavily oversubscribed placement at 4.6 cents.
BNNLF BMN

 
Bannerman Resources to lift cash position as uranium market awakens

2018-06-06 proactiveinvestors.com.au
Bannerman Resources Ltd (ASX:BMN) remains focused on the Etango project in Namibia, which hosts a resource of 271 million pounds of uranium.
BNNLF BMN

16
Bannerman Resources to benefit from cost reductions at Etango

2018-05-08 proactiveinvestors.com.au
Bannerman Resources Limited (ASX:BMN), like most players in the uranium sector, has had its share of challenges.
RTPPF RIO RIO BNNLF RIO RTNTF BMN

16
Bannerman Resources continues to progress uranium project in Namibia

2018-04-30 proactiveinvestors.com.au
Bannerman Resources Limited (ASX:BMN) is continuing to make steady progress at its Etango Uranium Project in Namibia, successfully completing a membrane study during the March quarter.
PDN PALAY PALAF RTPPF RIO RIO PDN BNNLF RIO RTNTF BMN

16
Membrane Study delivers cost savings to Etango

2018-04-11 globenewswire
PERTH, Australia, April 11, 2018 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN) (NSX:BMN) (Bannerman or the Company) is pleased to announce that the Etango Membrane Study has been completed successfully, delivering substantial reagent/operating cost reductions along with forecast capital savings, the final quantum of which is to be confirmed in the Etango Definitive Feasibility Study Update (DFS Update).
RTPPF RIO RIO BNNLF RIO RTNTF BMN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...